New combo therapy aims to stop mesothelioma return after surgery

NCT ID NCT05932199

Recruiting now Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 30 times

Summary

This study tests whether a combination of immunotherapy drugs (durvalumab and tremelimumab) alone or with chemotherapy can help people with a type of lung cancer called pleural mesothelioma that can be removed with surgery. The goal is to see if these treatments can keep the cancer from coming back for at least a year after surgery. About 52 adults will take part, and the study compares results to past data.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MESOTHELIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Baylor St Lukes
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Duke Cancer Institute
NOT_YET_RECRUITING

Durham, North Carolina, 27710, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MESOTHELIOMA